QTRX (Quanterix) Cash And Cash Equivalents : $56.7 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Quanterix Cash And Cash Equivalents?

Quanterix's quarterly cash and cash equivalents declined from Jun. 2024 ($47.00 Mil) to Sep. 2024 ($29.34 Mil) but then increased from Sep. 2024 ($29.34 Mil) to Dec. 2024 ($56.71 Mil).

Quanterix's annual cash and cash equivalents declined from Dec. 2022 ($338.74 Mil) to Dec. 2023 ($174.42 Mil) and declined from Dec. 2023 ($174.42 Mil) to Dec. 2024 ($56.71 Mil).

Quanterix Cash And Cash Equivalents Historical Data

The historical data trend for Quanterix's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quanterix Cash And Cash Equivalents Chart

Quanterix Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

181.58

396.47

338.74

174.42

56.71

Quanterix Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															174.42	45.28	47.00	29.34	56.71

Quanterix Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Quanterix (NAS:QTRX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Quanterix Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Quanterix's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Quanterix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quanterix Corp (NAS:QTRX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Middlesex Turnpike, Billerica, MA, USA, 01821

Website

https://www.quanterix.com

Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.

Executives

David R Walt	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Masoud Toloue	officer: President, Quanterix & Dx	C/O QUANTERIX CORP, 900 MIDDLESEX TURNPIKE, BILLERICA MA 01821
Laurie J Olson	director	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
William P Donnelly	director	C/O INGERSOLL RAND INC., 525 HARBOUR PLACE DRIVE, SUITE 600, DAVIDSON NC 28036
Vandana Sriram	officer: Chief Financial Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Brian J Blaser	director	561 CIRCLE LANE, LAKE FOREST IL 60045
Michael A Doyle	officer: CFO and Treasurer	C/O EASYLINK SERVICES CORPORATION, 33 KNIGHTSBRIDGE ROAD, PISCATAWAY NJ 08854
Sarah E. Hlavinka	director	2111 N MOLTER RD, LIBERTY LAKE WA 99019
Paul M Meister	director	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
John J Fry	officer: General Counsel & Secretary	8 CENTENNIAL DRIVE, PEABODY MA 01960
E Kevin Hrusovsky	director, officer: EC, President & CEO	68 ELM STREET, HOPKINTON MA 01748
Karen Flynn	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
David C. Duffy	officer: SVP R&D and CTO	C/O QUANTERIX CORPORATION, 113 HARTWELL AVENUELE, LEXINGTON MA 02421
Dawn Mattoon	officer: Sr VP, Stgc Mrktg & Assay Tech	113 HARTWELL AVENUE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421